Aparajita Hoskote Chourasia, Ph.D.

Aparajita Hoskote Chourasia, Ph.D. is a trained and experienced cancer biologist, leading the biology effort for development of targeted protein degraders at BioTheryX. She has been instrumental in identifying targets and establishing assays to assist in drug discovery efforts, and has contributed to the development of intellectual property at the company. A goal-oriented professional with strong analytical and communication skills who has demonstrated collaborative work in highly diverse teams comprising of scientists, academicians and clinicians. She has accrued expertise in molecular pathways in cancer, tumor metabolism, tumor models, inflammation, and assay development while working at Veridex (a Johnson & Johnson company), Novartis Institutes for Biomedical Research and the Brigham and Women Hospital (teaching affiliate of Harvard Medical School). Dr. Chourasia earned her Ph.D. in Cancer Biology from the University of Chicago, where her research focused on the tumor suppressive function of BNIP3 mediated mitochondrial autophagy in mammary and 
pancreatic tumorigenesis and its potential as a critical biomarker for early stage disease diagnosis. Her work led to successful NIH-funded research awards and peer reviewed research articles and reviews.